+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Company Analysis: Eli Lilly

The publisher explores Eli Lilly’s prescription pharmaceutical performance and outlook over 2019-29.

Snapshot
  • Overview - Eli Lilly’s prescription pharmaceutical business has been reversing recent declines and will grow out to 2029.
  • Key themes - [1] Diabetes sales will peak in the early 2020s, as key patent expirations will only be partially offset by strong biosimilar growth [2] Oncology portfolio will be a growth driver through the forecast period [3] Eli Lilly will remain active in business development (Loxo Oncology, Dermira) to bolster development pipeline.
Model updates (3 November 2020)
  • Trajenta royalties adjusted lower in the US
  • Trulicity forecast adjusted lower in the US
  • Jardiance royalties adjusted lower in the US.
Model updates (3 August 2020)
  • Verzenio forecast adjusted higher due to recent results of Phase III monarchE study in adjuvant breast cancer
  • Retevmo forecast adjusted higher due to initial launch trends
  • Reyvow forecast adjusted lower due to initial launch trends.
Model updates (2 June 2020)
  • Trulicity forecast adjusted higher
  • Jardiance royalties forecast adjusted lower due to amendment of agreement between Boehringer Ingelheim and Eli Lilly
  • Trajenta royalties forecast adjusted lower due to amendment of agreement between Boehringer Ingelheim and Eli Lilly
  • LY900014 forecast adjusted higher due to earlier-than-expected approval in Europe and Japan
  • Olumiant forecast adjusted lower in the US
  • Tyvyt forecast added.
Model updates (28 February 2020)
  • Trulicity forecast adjusted due to sustained robust volume growth globally
  • Jardiance royalties forecast adjusted higher due to sustained leadership in the SGLT-2 inhibitor class
  • Taltz forecast adjusted higher due to strong prescription growth in both dermatology and rheumatology
  • Verzenio forecast adjusted lower to better align with launch trajectory and trends in the CDK4/6 market
  • LOXO-292 name changed to selpercatinib; forecast pulled forward due to earlier-than-expected regulatory filings
  • LY3298176 name changed to tirzepatide
  • Pegilodecakin forecast removed after failures of CYPRESS 1 and CYPRESS 2 in non-small cell lung cancer
  • Tanezumab forecast added
  • Lebrikizumab forecast added due to acquisition of Dermira
  • Qbrexza forecast added due to acquisition of Dermira.
Note: Product cover images may vary from those shown
Company Background
  • Company Overview
  • Key Metrics
  • SWOT Analysis
  • Key Drug & Company Information
  • Company Comparison
Recent Earnings Review
  • Earnings Overview
  • Pharma Insights Analysis
Company Forecast
  • Prescription Pharmaceuticals Sales Outlook
  • Branded Drug Outlook
  • Launch Profile Outlook
  • Therapy Area Outlook
  • Regional Sales Outlook
  • Lifecycle Analysis
Company Profile
  • Marketed & Pipeline Drugs
  • Recent Events & Analyst Opinions
  • Upcoming Catalysts
  • Recent Insights
Clinical Trial Overview
  • Clinical Trial Snapshot
  • Clinical Trials by Country
  • Clinical Trials by Status and Phase
  • Clinical Trials by Drug
Note: Product cover images may vary from those shown
Adroll
adroll